Clinical Trials Logo

Lipid Metabolism Disorders clinical trials

View clinical trials related to Lipid Metabolism Disorders.

Filter by:

NCT ID: NCT06015620 Recruiting - Hypertension Clinical Trials

Comorbidities Resolution After MGB Surgery and Change in Body Composition

MOGAMBO
Start date: September 1, 2023
Phase:
Study type: Observational

This observational study aims to learn about the correlation between the improving comorbidities associated with obesity after MGB (Mini-Gastric Bypass) surgery and changes in body composition in morbidly obese patients. The main questions it aims to answer are: To study the correlation between the improving comorbidities associated with obesity after MGB(Mini-Gastric Bypass) surgery and changes in body composition. Other objectives are: - Changes in the parameters of the metabolic syndrome after surgery - Changes in the cardiovascular risk biomarkers after metabolic surgery - Emergence in complications arising out of surgery requiring any intervention or causing a prolonged hospital stay, or requiring additional outpatient visits. Type of Study: An observational study in which participants with morbid obesity will undergo mini-gastric bypass surgery as per routine protocol. No separate experimental interventions will be done in the study for the participants.

NCT ID: NCT05973474 Not yet recruiting - Clinical trials for Cardiovascular Diseases

The Atherogenic Index of Plasma(AIP) in Patients With Atrial Fibrillation

Start date: July 30, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about The Atherogenic Index of Plasma(AIP) in patients with atrial fibrillation(AF). The main questions it aims to answer are: (1)To investigate the correlation between AIP and the occurrence rate of AF. (2) To investigate the correlation between AIP and the occurrence rate of cardiovascular outcome events (MACE events, heart failure, embolism events) in patients with AF. Patients's clinical data including medical history, laboratory tests, and imageological examination will be collected and further analysed.

NCT ID: NCT05971017 Completed - Clinical trials for Glucose Metabolism Disorders

Health Effects of Biostimulated Lettuce in Human

NUTRIWEED23
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The aim of the project is to study the influence of biostimulate crops on a healthy population in order to assess influence on hematological parameters and specific metabolism (glucose, lipid, iron, bone) and gut and lipid hormones. Secondary outcome will be to find out micronutrient presence in urine and serum. The use of biostimulation in modern agriculture has rapidly expanded in recent years, owing to their beneficial effects on crop yield and product quality, which have come under the scope of intensive research.

NCT ID: NCT05968235 Completed - Vitiligo Clinical Trials

Correlation of Glucose and Lipid Metabolism Levels With Vitiligo

Start date: February 1, 2020
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to compare serum glucose and lipid metabolism levels between health volunteers and vitiligo patients. The main question it aims to answer is whether vitiligo is related to glucose and lipid metabolism disorders. Participants will complete a vitiligo questionnaire and test serum levels of indicators related to glucose and lipid metabolism. Researchers will compare vitiligo patients with healthy volunteers to see if there is a correlation between vitiligo and disorders of glucose and lipid metabolism.

NCT ID: NCT05962190 Recruiting - Adiposity Clinical Trials

Short-term Fat Overfeeding on the Effects of Liver Metabolism

FOS
Start date: February 15, 2023
Phase: N/A
Study type: Interventional

Despite work showing the overconsumption of saturated fatty acids (SFA) to be metabolically deleterious, debate continues about whether there is a link between SFA and cardiovascular disease risk. To explore this, we are undertaking a human in vivo parallel-design study, comparing two isocaloric high-fat diets; one enriched with SFA and the other enriched with unsaturated fatty acids (UFAs), to determine the impact of dietary fat composition on postprandial metabolism, liver fat, cardiac fat and cardiac function.

NCT ID: NCT05887180 Active, not recruiting - Type 2 Diabetes Clinical Trials

PräVaNet - Structured, Intersectoral, Multiprofessional, Digitized Program to Optimize Cardiovascular Prevention

PräVaNet
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

PräVaNet is a prospective, 1:1 randomized, controlled trial to investigate the efficacy of a new, digitalized prevention strategy ("ePrevention") in cardiovascular high-risk patients with type 2 diabetes mellitus in the outpatient sector.

NCT ID: NCT05779644 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

Start date: February 23, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

NCT ID: NCT05762263 Active, not recruiting - Blood Pressure Clinical Trials

The Effect of Flexitarian, Time-restricted Eating on Cardiometabolic Traits in Normal Weight, Young Men

FlexiFast
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

The goal of this factorial randomized controlled trial is to find out whether time-restricted eating and flexitarian diet (on its own and combined) can improve cardiometabolic health markers in normal weight, young men with metabolic abnormalities? Participants will be assigned to four groups: control, flexitarian, time-restricted eating and time-restricted eating + flexitarian. Investigators will look for men with elevated fasting blood glucose or blood lipids level or blood pressure and with normal body weight and waistline. Participants from the flexitarian group will be asked to follow a diet that has been carefully designed for them by the PI and dietitian for the period of 8 weeks. Participants from the control group will receive general healthy eating recommendations. We aim to investigate if the experiment had any effect on changes in metabolic, inflammation and nutritional markers, blood pressure and body weight and composition. Also, the effect of diets on men's sleep, general wellbeing and satisfaction with treatment will be investigated. The proposed study can test a potentially effective nutritional intervention which is feasible to adopt and sustainable (in line with recent planetary diet recommendations). Confirming its effectiveness can fill the research gap, providing new knowledge and approach to the prevention and treatment of metabolic abnormalities in young, lean men.

NCT ID: NCT05760248 Active, not recruiting - Clinical trials for Subcutaneous Fat Disorder

Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity

Start date: May 4, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test the safety and effectiveness of an injection study drug in decreasing bilateral flank adiposity. The main question it aims to answer is: •How safe and effective is the injection study drug in removing bilateral flank adiposity compared to a placebo? Participants will be: - Be given injections every month for 5 months over the right and left flanks. - Be asked to be seen in the clinic for 13 visits and 3 phone call visits during a duration of 1 year.

NCT ID: NCT05742841 Completed - Lipid Disorder Clinical Trials

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

EMERALD
Start date: March 8, 2023
Phase: Phase 4
Study type: Interventional

The EMERALD intervention involves 1) ordering an Emergency Department (ED) lipid panel, 2) calculating 10-year Atherosclerotic cardiovascular disease (ASCVD) risk using the Pooled Cohort Equations, 3) prescribing a moderate- or high-intensity statin if applicable, and 4) referring patients to outpatient care (primary care, preventive cardiology, or general cardiology, depending on risk level).